Hematopoietic reprogramming reflects the selective and evolutionarily conserved engagement of transcription factor networks that encode innate immune memory in long-lived stem cells.
The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.
The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.
Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly ...
(GLOBE NEWSWIRE) -- (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement ...
A study published in Nature looks at COVID-19 mRNA vaccines and the immune response to tumours during immunotherapy. Prof Andrew Beggs, MRC Senior Clinical Fellow and Consultant Colorectal Surgeon, ...
Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as ...
Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in ...
The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.
Data from investigator-initiated Phase II selected for Proffered Paper oral presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback